AU2017363256B2 - Allogeneic tumor cell vaccine - Google Patents

Allogeneic tumor cell vaccine Download PDF

Info

Publication number
AU2017363256B2
AU2017363256B2 AU2017363256A AU2017363256A AU2017363256B2 AU 2017363256 B2 AU2017363256 B2 AU 2017363256B2 AU 2017363256 A AU2017363256 A AU 2017363256A AU 2017363256 A AU2017363256 A AU 2017363256A AU 2017363256 B2 AU2017363256 B2 AU 2017363256B2
Authority
AU
Australia
Prior art keywords
seq
cells
cell line
tumor cell
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017363256A
Other languages
English (en)
Other versions
AU2017363256A1 (en
Inventor
Frank BORRIELLO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alloplex Biotherapeutics
Original Assignee
Alloplex Biotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alloplex Biotherapeutics filed Critical Alloplex Biotherapeutics
Publication of AU2017363256A1 publication Critical patent/AU2017363256A1/en
Application granted granted Critical
Publication of AU2017363256B2 publication Critical patent/AU2017363256B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4233—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2017363256A 2016-11-22 2017-11-22 Allogeneic tumor cell vaccine Active AU2017363256B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425424P 2016-11-22 2016-11-22
US62/425,424 2016-11-22
PCT/US2017/063016 WO2018098279A1 (en) 2016-11-22 2017-11-22 Allogenic tumor cell vaccine

Publications (2)

Publication Number Publication Date
AU2017363256A1 AU2017363256A1 (en) 2019-05-23
AU2017363256B2 true AU2017363256B2 (en) 2024-04-18

Family

ID=62195656

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017363256A Active AU2017363256B2 (en) 2016-11-22 2017-11-22 Allogeneic tumor cell vaccine

Country Status (6)

Country Link
US (2) US11058752B2 (enExample)
EP (1) EP3545001A4 (enExample)
JP (2) JP7629178B2 (enExample)
KR (2) KR20190100200A (enExample)
AU (1) AU2017363256B2 (enExample)
WO (1) WO2018098279A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201810871WA (en) 2016-07-25 2019-01-30 Us Health Methods of producing modified natural killer cells and methods of use
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
EP3545001A4 (en) * 2016-11-22 2020-10-21 Alloplex Biotherapeutics ALLOGENIC TUMOR CELL VACCINE
US10731128B2 (en) 2016-11-22 2020-08-04 Alloplex Biotherapeutics, Inc. Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
CN112912389B (zh) 2018-06-19 2024-04-19 H·李·莫菲特癌症中心和研究所公司 使用i型干扰素和cd40配体的溶瘤病毒或抗原呈递细胞介导的癌症治疗
BR112021009634A2 (pt) * 2018-11-19 2021-08-10 Board Of Regents, The University Of Texas System gene suicida
AU2020264484A1 (en) 2019-05-01 2021-11-04 Adoc Ssf, Llc Compositions and methods for the treatment of cancer using a CDB engineered T cell therapy
WO2020232408A1 (en) * 2019-05-15 2020-11-19 Genocea Biosciences, Inc. Treatment methods
EP3976816A4 (en) * 2019-05-28 2023-10-25 Case Western Reserve University COMPOSITIONS AND METHODS FOR PRESERVING DNA METHYLATION
CN114222763A (zh) * 2019-06-19 2022-03-22 尤利乌斯·马克西米利安维尔茨堡大学 在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点
AU2020371619A1 (en) * 2019-10-22 2022-05-12 Alloplex Biotherapeutics Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
JP2023504659A (ja) * 2019-12-03 2023-02-06 ニューボーゲン，インコーポレイティド 腫瘍細胞ワクチン
EP4164750A4 (en) * 2020-06-11 2024-04-17 Alloplex Biotherapeutics Allogeneic tumor cell vaccine
US20230257703A1 (en) * 2020-06-19 2023-08-17 Iowa State University Research Foundation, Inc. Nanoscale polymeric micellar scaffolds for rapid and efficient antibody production
EP4526457A2 (en) * 2022-06-30 2025-03-26 Meridian Therapeutics, Inc. A vaccine composition of cells expressing a lentiviral vector and methods of using

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297189A1 (en) * 2003-12-30 2010-11-25 Mologen Ag Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882654A (en) * 1989-11-03 1999-03-16 Morton; Donald L. Polyvalent melanoma vaccine
AU677165B2 (en) 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens
WO1998006746A2 (en) 1996-08-16 1998-02-19 The Johns Hopkins University School Of Medicine Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
WO1999028349A2 (en) 1997-12-02 1999-06-10 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
WO2001009303A2 (en) * 1999-07-30 2001-02-08 Vical Inc. Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
US20020006413A1 (en) 2000-01-27 2002-01-17 Sobol Robert E. Genetically engineered tumor cell vaccines
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
WO2003045428A2 (de) 2001-11-30 2003-06-05 Medigene Aktiengesellschaft Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
EP1667701A4 (en) 2003-09-26 2007-02-14 Univ Miami TUMOR VACCINE
EP2032173A4 (en) * 2006-06-06 2011-03-30 Univ Rochester HELPFREE-FREE HERPESVIRUS AMPLICON PARTICLES AND ITS USE
US9642986B2 (en) 2006-11-08 2017-05-09 C. R. Bard, Inc. Resource information key for an insertable medical device
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
WO2009095033A1 (en) * 2008-01-31 2009-08-06 Agirx Limited Vaccine compositons
WO2011004201A1 (en) 2009-07-10 2011-01-13 Mark Lowdell Preserved compositions of activated nk cells and methods of using the same
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2016168197A1 (en) 2015-04-15 2016-10-20 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2016198470A2 (en) 2015-06-08 2016-12-15 Lophius Biosciences Gmbh Composition for determination of cell-mediated immune responsiveness
WO2017133175A1 (en) 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
US10731128B2 (en) * 2016-11-22 2020-08-04 Alloplex Biotherapeutics, Inc. Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
EP3545001A4 (en) * 2016-11-22 2020-10-21 Alloplex Biotherapeutics ALLOGENIC TUMOR CELL VACCINE
US11185586B2 (en) * 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
US20200123566A1 (en) * 2017-06-13 2020-04-23 Oncosec Medical Incorporated Multigene construct for immune-modulatory protein expression and methods of use
WO2020040327A1 (ko) * 2018-08-23 2020-02-27 광주과학기술원 시클로피록스의 hbv 코어조립 저해 용도
AU2019398202A1 (en) * 2018-12-11 2021-08-05 Oncosec Medical Incorporated Multigene construct for immune-modulatory protein expression and methods of use
EP4164750A4 (en) * 2020-06-11 2024-04-17 Alloplex Biotherapeutics Allogeneic tumor cell vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297189A1 (en) * 2003-12-30 2010-11-25 Mologen Ag Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine

Also Published As

Publication number Publication date
US12403186B2 (en) 2025-09-02
JP2023055758A (ja) 2023-04-18
AU2017363256A1 (en) 2019-05-23
US11058752B2 (en) 2021-07-13
WO2018098279A9 (en) 2018-07-05
JP7629178B2 (ja) 2025-02-13
EP3545001A4 (en) 2020-10-21
US20210236610A1 (en) 2021-08-05
KR20240024328A (ko) 2024-02-23
US20180185463A1 (en) 2018-07-05
EP3545001A1 (en) 2019-10-02
JP2020502262A (ja) 2020-01-23
WO2018098279A1 (en) 2018-05-31
KR20190100200A (ko) 2019-08-28

Similar Documents

Publication Publication Date Title
US12403186B2 (en) Allogeneic tumor cell vaccine
US10731128B2 (en) Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
US11185586B2 (en) Allogeneic tumor cell vaccine
EP3674328B1 (en) Chimeric antigen receptor (car) binding to bcma, and uses thereof
US20230074800A1 (en) Car-t cell therapies with enhanced efficacy
JP2019531056A (ja) 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CN110352068A (zh) 合成的免疫受体及其使用方法
JP2019514393A (ja) 細胞に基づくネオ抗原ワクチンおよびその使用
KR20190036551A (ko) Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
CN113286615A (zh) 用于治疗癌症的微生物和免疫调节剂的组合疗法
US20200352999A1 (en) Use and production of engineered immune cells to disrupt nfat-ap1 pathway transcription factors
US20210038659A1 (en) Combination therapy using a chimeric antigen receptor
JP7752424B2 (ja) シリアルキラーｔ細胞集団のインビトロ活性化及び拡大、ならびに腫瘍細胞殺傷細胞を有するがん患者の受動免疫化のための組成物及び方法
Moran et al. Immunotherapy expands and maintains the function of high-affinity tumor-infiltrating CD8 T cells in situ
Chambers et al. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors
JP2025163127A (ja) 同種異系腫瘍細胞ワクチン
CN114588255A (zh) 基于mRNA的肿瘤疫苗及其制备和联合抗癌方法
KR20240007911A (ko) Cd5-양성 암을 표적화하기 위한 키메라 항원 수용체
KR20230084470A (ko) 면역 세포 기능의 향상
CN115996746A (zh) 经基因组修饰以表达正交受体的人免疫细胞
CN116916944A (zh) 基于免疫刺激性细菌的疫苗、治疗剂和rna递送平台
WO2023107898A1 (en) Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)